Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I and Randomized Phase II Trial of Radium-223 Dichloride, M3814, &Amp; Avelumab in Advanced Metastatic Castrate-Resistant Prostate Cancer (mCRPC)

NCT04071236 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT04071236
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04071236 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I and Randomized Phase II Trial of Radium-223 Dichloride, M3814, &Amp; Avelumab in Advanced Metastatic Castrate-Resistant Prostate Cancer (mCRPC)
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
October 14, 2020
Completion date
April 30, 2027
Enrollment
90 (estimated)
Sites
32

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic castration-resistant prostate carcinoma, metastatic malignant neoplasm in the bone, metastatic malignant neoplasm in the lymph nodes, stage ivb prostate cancer ajcc v8